Spago Nanomedical AB (publ) has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical trial with the tumor selective contrast agent SpagoPix (SN123D). The trial will include up to 20 patients with confirmed breast cancer.
The primary objective with the trial is to document safety, but another important objective is to investigate SN132D´s MRI-enhancing effects when used clinically in patients with solid tumors.
”There is need for better contrast agents for MRI of solid tumors. If SN132D provides good images, it can become an important part of healthcare in the treatment of breast cancer”, says Associate Professor Fredrik Wärnberg, coordinating investigator for the SPAGOPIX-01 trial and senior physician at Uppsala University Hospital.
“We are very pleased about the trial is now initiated and especially look forward to the the first images with SN132D in humans”, says CEO Mats Hansen.
SpagoPix (SN132D) is a contrast agent with potential to significantly improve cancer diagnostics with magnetic resonance imaging (MRI). Spago Nanomedical focus initially on imaging of breast cancer, a disease that affects approximately 2.1 million people annually. MRI is routinely used today for screening, diagnostics or tumor staging in 15-30% of all breast cancer patients but the need for better precision is substantial.
Trial details and updates will be published on www.clinicaltrials.gov.
For further information, contact Mats Hansen, VD Spago Nanomedical AB, +46 46 81188, email@example.com.